Influence of glutathione transferase T1 and M1 gene polymorphisms on the effectiveness of chemotherapy in patients with breast cancer based on clinical and morphological characteristics
Izabella S. Gulyan,
Evgeniya P. Bystritskaya,
Nadezhda Yu. Otstavnykh,
Oksana V. Perelomova,
Ekaterina V. Eliseeva,
Marina P. Isaeva,
Vladimir I. Apanasevich https://doi.org/10.37489/2588-0527-2025-3-13-20
EDN: CXWZZF
Abstract
Relevance. The steady increase in the incidence of breast cancer (BC), as well as associated mortality and disability of the population, determines the relevance of the search for effective treatment and prevention of this pathology.
Objective. Evaluation of differences in the effectiveness of chemotherapy for BC depending on the age, stage, and biological subtype of the tumor, considering the deletion status of the GSTT1 and GSTM1 genotypes in patients.
Materials and methods. Data from 132 patients with BC who received chemotherapy treatment from 2013 to 2021 were analyzed. Polymorphic GSTM1 and GSTT1 variants were genotyped using multiplex polymerase chain reaction, followed by analysis of the melting curves of the reaction products.
Results. The presence of the "null" genotype of GSTM1 and GSTT1 reduced the risk of relapse in patients with stage III disease by 0.52 times (95 % CI 0.29–0.89, p = 0.023) and 0.4 times, respectively (95 % CI 0.098–0.99, p = 0.049). Patients with luminal B HER2-positive breast cancer and GSTM1-0 had no fatalities. The risk of relapse was reduced in women with luminal B HER2-negative breast cancer subtype in the GSTM1-0 genotype group. In patients with luminal A, the overall survival (OS) with the GSTT1 wild type was 75.5 (±12.3) %, with GSTM1-0 there were no lethal outcomes (OR = 0.034, 95 % CI 0.02–0.045, p = 0.001), with luminal B HER2-negative subtypes, OS with the GSTT1 wild type was 69.9 (±8.5) % versus no lethal cases with the null genotype (OR = 0.035, 95 % CI 0.025–0.044, p = 0.001)).
Conclusion. The results of our study showed a significant effect of the GSTT1 and GSTM1 gene deletion polymorphism on relapse-free survival in patients with stage III disease and hormone-dependent breast cancer.
About the Authors
Izabella S. Gulyan
Pacific State Medical University; Far Eastern Federal University
Russian Federation
Competing Interests:
Russian Federation
Izabella S. Gulyan — Assistant at the Institute of Surgery; oncologist of the Medical Complex FEFU,
Vladivostok.
Competing Interests:
The authors declare no obvious or potential conflicts of interest related to the publication of this article.
Evgeniya P. Bystritskaya
G.B. Elyakov Pacific Institute of Bioorganic Chemistry, Far Eastern Branch RAS
Russian Federation
Competing Interests:
Russian Federation
Evgeniya P. Bystritskaya — Junior Researcher at the Marine Biochemistry Laboratory,
Vladivostok.
Competing Interests:
The authors declare no obvious or potential conflicts of interest related to the publication of this article.
Nadezhda Yu. Otstavnykh
G.B. Elyakov Pacific Institute of Bioorganic Chemistry, Far Eastern Branch RAS
Russian Federation
Competing Interests:
Russian Federation
Nadezhda Yu. Otstavnykh — Junior Researcher at the Marine Biochemistry Laboratory,
Vladivostok.
Competing Interests:
The authors declare no obvious or potential conflicts of interest related to the publication of this article.
Oksana V. Perelomova
Pacific State Medical University
Russian Federation
Competing Interests:
Russian Federation
Oksana V. Perelomova — Senior Lecturer at the Institute of Fundamental Principles and Information Technologies in Medicine,
Vladivostok.
Competing Interests:
The authors declare no obvious or potential conflicts of interest related to the publication of this article.
Ekaterina V. Eliseeva
Pacific State Medical University
Russian Federation
Competing Interests:
Russian Federation
Ekaterina V. Eliseeva — PhD, Dr. Sci. (Med.), Professor, Head of Department of General and Clinical Pharmacology,
Vladivostok.
Competing Interests:
The authors declare no obvious or potential conflicts of interest related to the publication of this article.
Marina P. Isaeva
G.B. Elyakov Pacific Institute of Bioorganic Chemistry, Far Eastern Branch RAS
Russian Federation
Competing Interests:
Russian Federation
Marina P. Isaeva — PhD, Сand. Sci. (Med.), Head of the Laboratory of Marine Biochemistry,
Vladivostok.
Competing Interests:
The authors declare no obvious or potential conflicts of interest related to the publication of this article.
Vladimir I. Apanasevich
Pacific State Medical University
Russian Federation
Competing Interests:
Russian Federation
Vladimir I. Apanasevich — PhD, Dr. Sci. (Med.), Professor of the Institute of Surgery,
Vladivostok.
Competing Interests:
The authors declare no obvious or potential conflicts of interest related to the publication of this article.
References
1. Злокачественные новообразования в России в 2023 году (заболеваемость и смертность) / под ред. А.Д. Каприна [и др.] М.: МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2024. илл. 276 с. [Malignant Neoplasms in Russia in 2023 (Incidence and Mortality) / Ed by AD Kaprin [et al.] Moscow: PA Herzen Moscow Research Institute of Oncology — Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, 2024. (In Russ.)]. ISSN 1726-2891.
2. Personalized Medicine Coalition (PMC). [Электронный ресурс]. Доступно по: http://www.personalizedmedicinecoalition.org. Ссылка активна на 28.10.2025.
3. Bukowski K, Kciuk M, Kontek R. Mechanisms of Multidrug Resistance in Cancer Chemotherapy. Int J Mol Sci. 2020 May 2;21(9):3233. doi: 10.3390/ijms21093233.
4. McDermott JH, Newman W. Introduction to pharmacogenetics. Drug Ther Bull. 2023 Nov;61(11):168-172. doi: 10.1136/dtb.2023.000009.
5. Hertz DL, Bousman CA, McLeod HL, et al. Recommendations for pharmacogenetic testing in clinical practice guidelines in the US. Am J Health Syst Pharm. 2024 Aug 12;81(16):672-683. doi: 10.1093/ajhp/zxae110.
6. Xiang Z, Snouwaert JN, Kovarova M, et al. Mice lacking three Loci encoding 14 glutathione transferase genes: a novel tool for assigning function to the GSTP, GSTM, and GSTT families. Drug Metab Dispos. 2014 Jun;42(6):1074-83. doi: 10.1124/dmd.113.056481.
7. Ye J, Mu YY, Wang J, He XF. Individual effects of GSTM1 and GSTT1 polymorphisms on cervical or ovarian cancer risk: An updated meta-analysis. Front Genet. 2023 Jan 12;13:1074570. doi: 10.3389/fgene.2022.1074570.
8. Гулян И.С., Быстрицкая Е.П., Чернышева Н.Ю. и др. Делеци- онный полиморфизм генов глутатион-S-трансфераз (GSTT1, GSTM1) у пациенток с раком молочной железы в Приморском крае. Опухоли женской репродуктивной системы. 2020;16(3):25-31. [Gulyan IS, Bystritskaya EP, Chernysheva NY et al. Deletion polymorphism of glutathione S-transferases genes (GSTT1, GSTM1) in patients with breast cancer in Primorye region. Opukholi zhenskoy reproduktivnoy systemy = Tumors of female reproductive system. 2020;16(3):25-31. (In Russ.)]. doi: 10.17650/1994-4098-2020-16-3-25-31.
9. Тихомирова АВ. Критерии оценки клинической эффективности противоопухолевых лекарственных средств. Ведомости Научного центра экспертизы средств медицинского применения. 2019;9(1):34-40. [Tikhomirova AV. Criteria for evaluation of clinical efficacy of anticancer medicines. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya = Тhе Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2019;9(1):34-40. (In Russ.)]. doi: 10.30895/1991-2919-2019-9-1-34-40.
10. Бурденный А.М., Лукина С.С., Заварыкина Т.М., и др. Фарма- когенетика лекарственных веществ при раке молочной железы и новые возможности улучшения их биодоступности. Патологическая физио- логия и экспериментальная терапия. 2019;64(4):137-150. [Burdennyy AM, Lukina SS, Zavarykina TM, et al. Pharmacogenetics of drugs in breast cancer and new approaches for improvement of their bioavailability. Patologicheskaya Fiziologiya i Eksperimental`naya Terapiya. (Pathological Physiology and Experimental Therapy, Russian Journal). 2019; 64(4): 137-150. (In Russ.)]. doi: 10.25557/0031-2991.2019.04.137-150.
11. Bosch TM, Meijerman I, Beijnen JH, Schellens JH. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet. 2006;45(3):253-85. doi: 10.2165/00003088-200645030-00003. PMID: 16509759.
12. Ambrosone CB, Sweeney C, Coles BF, et al. Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Res. 2001 Oct 1;61(19):7130-5. PMID: 11585745.
13. Soto-Quintana O, Zúñiga-González GM, Ramírez-Patiño R, et al. Association of the GSTM1 null polymorphism with breast cancer in a Mexican population. Genet Mol Res. 2015 Oct 26;14(4):13066-75. doi: 10.4238/2015.October.26.2.
14. Wang J, Wang T, Yin GY, et al. Glutathione S-transferase polymorphisms influence chemotherapy response and treatment outcome in breast cancer. Genet Mol Res. 2015 Sep 22;14(3):11126-32. doi: 10.4238/2015.September.22.6.
15. Mishra A, Chandra R, Mehrotra PK, et al. Glutathione S-transferase M1 and T1 polymorphism and response to neoadjuvant chemotherapy (CAF) in breast cancer patients. Surg Today. 2011 Apr;41(4):471-6. doi: 10.1007/s00595-009-4310-4.
16. Pacholak LM, Amarante MK, Guembarovski RL, et al. Polymorphisms in GSTT1 and GSTM1 genes as possible risk factors for susceptibility to breast cancer development and their influence in chemotherapy response: a systematic review. Mol Biol Rep. 2020 Jul;47(7):5495-5501. doi: 10.1007/s11033-020-05555-8.
17. Yuan Z, Li J, Hu R, et al. Predictive assessment in pharmacogenetics of XRCC1 gene on clinical outcomes of advanced lung cancer patients treated with platinum-based chemotherapy. Sci Rep. 2015 Nov 20;5:16482. doi: 10.1038/srep16482.
18. Yuan P, Yuan L, Xu BL, et al. Predictive potential role of glutathione S-transferases polymorphisms in response to chemotherapy and breast cancer prognosis. Genet Mol Res. 2015 Dec 11;14(4):16675-81. doi: 10.4238/2015.December.11.15.
19. Yang G, Shu XO, Ruan ZX, et al. Genetic polymorphisms in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma. Cancer. 2005 Jan 1; 103(1):52-8. doi: 10.1002/cncr.20729.
20. Lorentzen EH, Minami CA. Avoiding Locoregional Overtreatment in Older Adults With Early-Stage Breast Cancer. Clin Breast Cancer. 2024 Jun;24(4):319-327. doi: 10.1016/j.clbc.2024.02.004.
21. Loibl S, Poortmans P, Morrow M, et al. Breast cancer. Lancet. 2021 May 8;397(10286):1750-1769. doi: 10.1016/S0140-6736(20)32381-3. Epub 2021 Apr 1. Erratum in: Lancet. 2021 May 8;397(10286):1710. doi: 10.1016/S0140-6736(21)00838-2.
22. Campos CZ, Losi Guembarovski R, de Oliveira CEC, et al. Glutathione S-transferases deletions may act as prognosis and therapeutic markers in breast cancer. Clin Exp Med. 2018 Feb;18(1):27-35. doi: 10.1007/s10238-017-0461-6.
23. Almeida M, Soares M, Ramalhinho AC, et al. Prognosis of hormone- dependent breast cancer seems to be influenced by KEAP1, NRF2 and GSTM1 genetic polymorphisms. Mol Biol Rep. 2019 Jun;46(3):3213-3224. doi: 10.1007/s11033-019-04778-8.
Review
For citations:
Gulyan I.S., Bystritskaya E.P., Otstavnykh N.Yu., Perelomova O.V., Eliseeva E.V., Isaeva M.P., Apanasevich V.I. Influence of glutathione transferase T1 and M1 gene polymorphisms on the effectiveness of chemotherapy in patients with breast cancer based on clinical and morphological characteristics. Pharmacogenetics and Pharmacogenomics. 2025;(3):13-20. (In Russ.) https://doi.org/10.37489/2588-0527-2025-3-13-20. EDN: CXWZZF
Views:
47
JATS XML
Email this article 
Post a Comment 